GlaxoSmithKline PLC — Foreign Filer Report 2021

Oct 14, 2021

6-K 1 a1467p.htm DIRECTOR/PDMR SHAREHOLDING Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com Copyright 2021 Issuer Direct Corporation a1467p

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2021

Commission File Number 001-15170

GlaxoSmithKline plc

(Translation of registrant's name into English)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

GlaxoSmithKline plc (the ' Company ')

Transaction notification

| 1. — a) | Details of PDMR/person closely associated with them ('PCA') — Name | Ms E Walmsley | | | --- | --- | --- | --- | | b) | Position/status | Chief Executive Officer | | | c) | Initial notification/ amendment | Initial notification | | | 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | a) | Name | GlaxoSmithKline plc | | | b) | LEI | 5493000HZTVUYLO1D793 | | | 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | | | a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | | | b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 | | | c) | Price(s) and volume(s) | Price(s) | Volume(s) | | | | £14.2746 | 2,865.594 | | d) | Aggregated information | N/A (single transaction) | | | | Aggregated volume Price | | | | e) | Date of the transaction | 2021-10-12 | | | f) | Place of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them ('PCA') — Name | Mr R Connor | | | --- | --- | --- | --- | | b) | Position/status | President, Vaccines & Global Health | | | c) | Initial notification/ amendment | Initial notification | | | 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | a) | Name | GlaxoSmithKline plc | | | b) | LEI | 5493000HZTVUYLO1D793 | | | 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | | | a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | | | b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 | | | c) | Price(s) and volume(s) | Price(s) | Volume(s) | | | | £14.2746 | 2,809.310 | | d) | Aggregated information | N/A (single transaction) | | | | Aggregated volume Price | | | | e) | Date of the transaction | 2021-10-12 | | | f) | Place of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them ('PCA') — Name | Ms D Conrad | | | --- | --- | --- | --- | | b) | Position/status | SVP, Human Resources | | | c) | Initial notification/ amendment | Initial notification | | | 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | a) | Name | GlaxoSmithKline plc | | | b) | LEI | 5493000HZTVUYLO1D793 | | | 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | | | a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | | | b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 | | | c) | Price(s) and volume(s) | Price(s) | Volume(s) | | | | £14.2746 | 9.283 | | d) | Aggregated information | N/A (single transaction) | | | | Aggregated volume Price | | | | e) | Date of the transaction | 2021-10-12 | | | f) | Place of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them ('PCA') — Name | Mr J Ford | | | --- | --- | --- | --- | | b) | Position/status | SVP & General Counsel | | | c) | Initial notification/ amendment | Initial notification | | | 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | a) | Name | GlaxoSmithKline plc | | | b) | LEI | 5493000HZTVUYLO1D793 | | | 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | | | a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | | | b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 | | | c) | Price(s) and volume(s) | Price(s) | Volume(s) | | | | £14.2746 | 0.00003 | | d) | Aggregated information | N/A (single transaction) | | | | Aggregated volume Price | | | | e) | Date of the transaction | 2021-10-12 | | | f) | Place of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them ('PCA') — Name | Ms S Jackson | | | --- | --- | --- | --- | | b) | Position/status | SVP, Global Communications and CEO Office | | | c) | Initial notification/ amendment | Initial notification | | | 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | a) | Name | GlaxoSmithKline plc | | | b) | LEI | 5493000HZTVUYLO1D793 | | | 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | | | a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | | | b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 | | | c) | Price(s) and volume(s) | Price(s) | Volume(s) | | | | £14.2746 | 359.622 | | d) | Aggregated information | N/A (single transaction) | | | | Aggregated volume Price | | | | e) | Date of the transaction | 2021-10-12 | | | f) | Place of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them ('PCA') — Name | Mr D Jackson | | | --- | --- | --- | --- | | b) | Position/status | PCA of Ms S Jackson (SVP, Global Communications and CEO Office) | | | c) | Initial notification/ amendment | Initial notification | | | 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | a) | Name | GlaxoSmithKline plc | | | b) | LEI | 5493000HZTVUYLO1D793 | | | 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | | | a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | | | b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 | | | c) | Price(s) and volume(s) | Price(s) | Volume(s) | | | | £14.2746 | 168.283 | | d) | Aggregated information | N/A (single transaction) | | | | Aggregated volume Price | | | | e) | Date of the transaction | 2021-10-12 | | | f) | Place of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them ('PCA') — Name | Mr L Miels | | | --- | --- | --- | --- | | b) | Position/status | Chief Commercial Officer | | | c) | Initial notification/ amendment | Initial notification | | | 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | a) | Name | GlaxoSmithKline plc | | | b) | LEI | 5493000HZTVUYLO1D793 | | | 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | | | a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | | | b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 | | | c) | Price(s) and volume(s) | Price(s) | Volume(s) | | | | £14.2746 | 5,078.983 | | d) | Aggregated information | N/A (single transaction) | | | | Aggregated volume Price | | | | e) | Date of the transaction | 2021-10-12 | | | f) | Place of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them ('PCA') — Name | Mr D Redfern | | | --- | --- | --- | --- | | b) | Position/status | Chief Strategy Officer | | | c) | Initial notification/ amendment | Initial notification | | | 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | a) | Name | GlaxoSmithKline plc | | | b) | LEI | 5493000HZTVUYLO1D793 | | | 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | | | a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | | | b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 | | | c) | Price(s) and volume(s) | Price(s) | Volume(s) | | | | £14.2746 | 4,627.648 | | d) | Aggregated information | N/A (single transaction) | | | | Aggregated volume Price | | | | e) | Date of the transaction | 2021-10-12 | | | f) | Place of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them ('PCA') — Name | Mr R Simard | | | --- | --- | --- | --- | | b) | Position/status | President, Pharmaceuticals Supply Chain | | | c) | Initial notification/ amendment | Initial notification | | | 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | a) | Name | GlaxoSmithKline plc | | | b) | LEI | 5493000HZTVUYLO1D793 | | | 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | | | a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | | | b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 | | | c) | Price(s) and volume(s) | Price(s) | Volume(s) | | | | £14.2746 | 826.604 | | d) | Aggregated information | N/A (single transaction) | | | | Aggregated volume Price | | | | e) | Date of the transaction | 2021-10-12 | | | f) | Place of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them ('PCA') — Name | Mr P Thomson | | | --- | --- | --- | --- | | b) | Position/status | President, Global Affairs | | | c) | Initial notification/ amendment | Initial notification | | | 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | a) | Name | GlaxoSmithKline plc | | | b) | LEI | 5493000HZTVUYLO1D793 | | | 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | | | a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | | | b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 | | | c) | Price(s) and volume(s) | Price(s) | Volume(s) | | | | £14.2746 | 1,002.520 | | d) | Aggregated information | N/A (single transaction) | | | | Aggregated volume Price | | | | e) | Date of the transaction | 2021-10-12 | | | f) | Place of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them ('PCA') — Name | Ms K Thomson | | | --- | --- | --- | --- | | b) | Position/status | PCA of Mr P Thomson (President, Global Affairs) | | | c) | Initial notification/ amendment | Initial notification | | | 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | a) | Name | GlaxoSmithKline plc | | | b) | LEI | 5493000HZTVUYLO1D793 | | | 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | | | a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | | | b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 | | | c) | Price(s) and volume(s) | Price(s) | Volume(s) | | | | £14.2746 | 157.681 | | d) | Aggregated information | N/A (single transaction) | | | | Aggregated volume Price | | | | e) | Date of the transaction | 2021-10-12 | | | f) | Place of the transaction | London Stock Exchange (XLON) | |

| 1. — a) | Details of PDMR/person closely associated with them ('PCA') — Name | Ms D Waterhouse | | | --- | --- | --- | --- | | b) | Position/status | Chief Executive Officer of ViiV Healthcare | | | c) | Initial notification/ amendment | Initial notification | | | 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | | | a) | Name | GlaxoSmithKline plc | | | b) | LEI | 5493000HZTVUYLO1D793 | | | 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | | | a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 | | | b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021 | | | c) | Price(s) and volume(s) | Price(s) | Volume(s) | | | | £14.2746 | 201.857 | | d) | Aggregated information | N/A (single transaction) | | | | Aggregated volume Price | | | | e) | Date of the transaction | 2021-10-12 | | | f) | Place of the transaction | London Stock Exchange (XLON) | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

(Registrant)
Date: October
14, 2021
By:/s/ VICTORIA
WHYTE --------------------------
Victoria Whyte
Authorised
Signatory for and on
behalf
of GlaxoSmithKline plc